Day One Biopharmaceutical Analyst Ratings
Piper Sandler Keeps Their Buy Rating on Day One Biopharmaceuticals (DAWN)
HC Wainwright & Co. Reiterates Buy on Day One Biopharmaceutical, Maintains $40 Price Target
Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target
Day One Biopharmaceutical Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Biomea Fusion (BMEA), Day One Biopharmaceuticals (DAWN)
Bank of America Securities Reaffirms Their Sell Rating on Day One Biopharmaceuticals (DAWN)
Buy Rating on Day One Biopharmaceuticals: Ojemda's Market Potential and Strategic Commercialization
Day One Biopharmaceutical Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Amgen (AMGN) and Omnicell (OMCL)
Day One Biopharmaceutical Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Day One Biopharmaceuticals (DAWN)
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Biogen (BIIB) and Neurocrine (NBIX)
Day One Biopharmaceutical Analyst Ratings
Buy Rating on Day One Biopharmaceuticals Amid FDA Approval and Strong Market Prospects
Day One Biopharmaceutical Analyst Ratings
Buy Rating Affirmed for Day One Biopharmaceuticals on Strong Tovorafenib Prospects and Market Impact
Analysts Are Bullish on These Healthcare Stocks: OptimizeRx (OPRX), Day One Biopharmaceuticals (DAWN)
Buy Rating on Day One Biopharmaceuticals Ahead of Tovorafenib PDUFA Date and Potential for Market Disruption
Day One Biopharmaceutical Analyst Ratings